Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers July 28, 2017
Pharmacy Choice - News - Over-the-Counter Drugs - July 28, 2017

Pharmacy News

 Over-the-Counter Drugs
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

6/27/17 - Aralez Announces District Court Decision to Uphold VIMOVO (Naproxen/Esomeprazole Magnesium) Patents
MISSISSAUGA, Ontario, June 27, 2017/ PRNewswire/ Aralez Pharmaceuticals Inc. today announced that the United States District Court for the District of New Jersey upheld the validity of two patents owned by a subsidiary of Aralez and licensed to Horizon Pharma plc covering VIMOVO , and that Dr. Reddy's Laboratories Inc. and Dr. Reddy's Laborator
6/27/17 - Horizon Pharma plc Announces District Court Decision to Uphold VIMOVO (naproxen/esomeprazole magnesium) Patents
Horizon Pharma plc, a biopharmaceutical company focused on improving patients lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the United States District Court for the District of New Jersey upheld the validity of two Horizon Pharma pa
6/27/17 - ViaDerma, Inc. Receives National Drug Code (NDC) from the FDA for Prolayed, Its New OTC Drug for Premature Ejaculation for Men
ViaDerma, Inc., a specialty pharmaceutical company devoted to bringing new products to market, recently announced today that the Company has received its National Drug Code 69006-010-00 from the Food and Drug Administration for its new over the counter or OTC medication, Prolayed, a male genital desensitizer to delay onset of ejaculation.
6/26/17 - Eloxx Pharmaceuticals Receives a US$6 Million Investment from KIP and DCS to Advance a Novel Disease-Modifying Therapy Targeting Genetic Diseases Including Cystic Fibrosis
SAN DIEGO& REHOVOT, Israel& SEOUL, South Korea Today, Korea Investment Partners, DSC Investments, Sevion Therapeutics, Inc. and Eloxx Pharmaceuticals Ltd, a clinical stage company developing therapeutics for genetic diseases caused by nonsense mutations, announce a US $6 million investment in Eloxx Pharmaceuticals. Phil Frost, OPKO Health Inc.
6/26/17 - Global Markets for Allergy Diagnostics and Treatments is expected to reach $52.7 billion by 2021
This market is expected to increase from nearly $40.0 billion in 2016 to $52.7 billion in 2021 at a compound annual growth rate of 5.9% for 2016-2021.. Treatments market is expected to grow from $33.4 billion in 2016 to $44.4 billion in 2021 at a CAGR of 5.9% from 2016 through 2021.. Specific chapters that focus on testing and treatment in thre
6/26/17 - Patent Issued for Method for Evaluating Degradation Pathways for Pancreatin Active Pharmaceutical Agents (USPTO 9677114)
By a News Reporter-Staff News Editor at Pharma Business Week Scientific Protein Laboratories, LLC has been issued patent number 9677114, according to news reporting originating out of Alexandria, Virginia, by NewsRx editors. The patent's inventors are Akula, Anisha; Wang, Yan. This patent was filed on April 18, 2013 and was published online on Ju
6/26/17 - Sometimes the co-pay is more than the price
The efforts of the current Congress to change health insurance hardly encourage hope for controlling drug costs. This is a crisis that may not get the attention it deserves from the U.S. Senate as it carves up the House version of the American Health Care Act. In New York, our bottom-up push is about lowering prescription drug prices- an issue not
6/25/17 - Jacobson Pharma Announces 2017 Annual Results
HONG KONG, Jun 25, 2017 Jacobson Pharma Corporation Limited, a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries for the year ended 31 March 2017. These annual results are the first since the co
6/23/17 - Don't be overwhelmed in calculating drug levels in swine feed
By Ralph D. Wilson, Pharmgate Animal Health Since the first of the year, feed medications that were once readily available over-the-counter to treat swine diseases, now require the diagnosis and direction of a veterinarian. A stumbling block in the effort to fill out the Veterinary Feed Directive forms correctly is the space for listing the drug le
6/23/17 - GNW-News: NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML) (english)
NEJM publishes full analysis of Rydapt Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia. Novartis International AG/ NEJM publishes full analysis of Rydapt Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia. over a decade's collaboration with Alliance for Clinical Trials in.
6/23/17 - Jacobson Pharma Announces 2017 Annual Results
Jacobson Pharma Corporation Limited, a leading company engaged in the research, development, production, marketing and sale of generic drugs and proprietary medicines, has today announced its annual results of the Company and its subsidiaries for the year ended 31 March 2017. These annual results are the first since the company's listing in Hong Ko
6/23/17 - NEJM publishes full analysis of Rydapt (midostaurin) Phase III RATIFY trial in newly diagnosed FLT3-mutated acute myeloid leukemia (AML)
Novartis today announced that full results from the Rydapt Phase III RATIFY clinical trial were published in The New England Journal of Medicine 1. Top-line data from this study were previously presented during the plenary session at the American Society of Hematology Annual Meeting in 2015 2. "The data from the CALGB 10603/ RATIFY trial rein
6/23/17 - Novartis Kisqali (ribociclib) receives positive CHMP opinion as first-line treatment for HR+/HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor
Novartis International AG/ Novartis Kisqali receives positive CHMP opinion as first-line treatment for HR+/ HER2- locally advanced or metastatic breast cancer in combination with any aromatase inhibitor. *CHMP opinion based on pivotal Phase III trial that showed Kisqali plus letrozole reduced risk of disease progression or death by 44% over letr
6/23/17 - Patient-Focused Drug Development for Alopecia Areata; Public Meeting; Request for Comments
The public meeting is intended to allow FDA to obtain patients' perspectives on the impact of alopecia areata, including on daily life. FDA is also seeking patients' views on treatment approaches and decision factors taken into account when selecting a treatment. ADDRESSES: The public meeting will be held at the FDA White Oak Campus, 10903 New Hamp
6/22/17 - BioPharmX to Present Phase 2b Clinical Trial Acne Data at Alabama Dermatology Society Summer Symposium
BioPharmX Corporation, a specialty pharmaceutical company focusing on dermatology, will present results of its phase 2 b of BPX-01, a unique topical hydrophilic gel formulation of minocycline, at the Alabama Dermatology Society's Summer Symposium being held June 22-25 in Sandestin, Fla.. James Q. Del Rosso, founder of JDR Dermatology Research, La
6/22/17 - Dr. Craig Landau Appointed President and CEO Purdue Pharma L.P.
Today, The Board of Directors of the independently associated worldwide Purdue/ Napp/ Mundipharma network of companies announces that Dr. Craig Landau is appointed President and CEO for the U.S. operations, Purdue Pharma L.P., headquartered in Stamford, Connecticut, with immediate effect, and will retain responsibility for Purdue Pharma.
6/22/17 - HEALTH & SUPPORT
Alzheimer's Association to host caregivers education series. The next program in this series will be held from 4-6 p.m. June 22 at the North Shore Elder Services, 300 Rosewood Drive, Danvers. Held 7-8: 30 p.m. on the last Wednesday of each month in the doctors' conference room at Beverly Hospital, 85 Herrick St., Beverly.
6/22/17 - Kalo Donates 250,000th EVZIO (naloxone HCl injection) Auto-injector to Help Fight Opioid Overdose Epidemic
From their initial concept of a compact auto-injector with innovative features, all the way to FDA approval, it took years of hard work and many millions of dollars invested in research and development. Kalo is proud to have more than 100 domestic and international issued patents and FDA approvals for three products in the last four years.
6/22/17 - The Life Sciences Report Examines How a Fast-Growing Pharma Company Prepares to Launch OTC Nasal Spray
A San Diego- based pharmaceutical company that focuses on over-the-counter medications reported strong Q1/17 results and expects to begin marketing a nasal spray by the end of the year. Included in this article is: Innovus Pharmaceuticals Inc.. Innovus Pharmaceuticals Inc., a rapidly growing, San Diego- based pharmaceutical company that focuses on.
6/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg
Release date- 20062017- PORT WASHINGTON, N.Y.- ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA approve
6/21/17 - ACETO Subsidiary, Rising Pharmaceuticals, Launches Chlorthalidone Tablets, 25 mg and 50 mg, and Glipizide Extended Release Tablets, 2.5 mg, 5 mg and 10 mg [Tehran Times (Iran)]
-ACETO Corporation, an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched an FDA- approved generic version of Chlorthalidone Tablets,
6/21/17 - Neos Therapeutics Announces FDA Approval of Cotempla XR-ODT (methylphenidate) Extended-Release Orally Disintegrating Tablets for the Treatment of ADHD in Patients 6 to 17 Years Old [Sudan Tribune]
-Neos Therapeutics, Inc., a pharmaceutical company focused on developing, manufacturing and commercializing innovative extended-release products using its proprietary modified-release drug delivery and orally disintegrating tablet technologies, today announced that the U.S. Food and Drug Administration approved Cotempla XR-ODT, the first and only..
6/21/17 - Nutra Pharma Announcing Launch of Luxury Feet
Nutra Pharma Corporation, a biotechnology company marketing Nyloxin and Pet Pain-Away? in the over-the-counter pain management market, announced today that they are expanding their product line with the introduction of Luxury Feet; an over-the-counter pain reliever and anti-inflammatory product that is designed for women who experience pain or
6/21/17 - Pet supplements may not be worth the effort
Every year pet owners spend over $60 billion on their pets. This number represents everything from clothing to very pricey medical treatments. In the last few years, dietary supplements for pets have seen a large increase in popularity.
6/20/17 - 7 New Options for Sleep-Onset Insomnia
In the past three years, several therapies have emerged for treating patients who have difficulty initiating sleep. We profile prescription and over-the-counter treatments, including explaining their mechanism of action, efficacy studies, and reimbursement status.
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2017 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool
Drug Therapy Management Series Part III: Geriatric Disorders
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2017 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415